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Effects of high-affinity nerve growth factor 
receptor inhibitors on symptoms in NC/Nga 
mice
Nerve growth factor 
(NGF) is an impor-
tant substance in the 
skin. However, the 
direct link between 
NGF and pruritic 
diseases such as 
atopic dermatitis is not yet fully understood. To determine 
the significance of NGF receptors in the pathogenesis of 
atopic dermatitis, the effects of high-affinity NGF receptor 
inhibitors on the symptoms of NC/Nga mice were evaluated. 
Repeated applications of inhibitors significantly improved 
the established dermatitis and scratching behaviour, and 
decreased nerve fibres in the epidermis. We suggest that 
NGF plays an important role in the pathogenesis of atopic 
dermatitis-like skin lesions via the high-affinity NGF recep-
tor. Br J Dermatol 2007; 156:241–246.
Oral retinoic acid metabolism blocking agent 
Rambazole™: a novel treatment option for 
plaque psoriasis?
The systemic all-trans retinoic acid metabolism blocking agent 
Rambazole™ increases intracellular levels of endogenous all-
trans retinoic acid. Well-known effects of retinoic acid are nor-
malization of epithelial growth and differentiation. Whereas 
the clinical results of a recently performed phase IIa trial in 
psoriasis will be presented in the near future, in the current 
study Bovenschen et al. assessed the dynamics of epidermal 
proliferation, keratinization and immunocytes in lesional 
psoriasis during treatment with Rambazole™ mg daily for 8 
weeks. Significant improvements are presented for plaque 
severity scores, epidermal proliferation and differentiation 
of keratinocytes. In addition, a nonsignificant reduction pat-
tern was observed for lesional (NK-) T-cell subsets at week 8. 
Rambazole™ might therefore be a promising future treatment 
option for plaque psoriasis. Br J Dermatol 2007; 156:263–270.
Association between cutaneous melanoma, 
Breslow thickness and vitamin D receptor 
BsmI polymorphism
This study analyses the association between three vitamin 
D receptor (VDR) gene polymorphisms (FokI, A-1012G and 
BsmI, detected by restriction fragment length polymorphism 
analysis) and malignant melanoma (MM), comparing 101 
patients with MM and 101 healthy donors. These polymor-
phisms might have clinical relevance influencing antiprolif-
erative and prodifferentiation effects of vitamin D and T cell-
mediated immunity. Multivariate logistic regression analysis 
showed that MM was significantly associated with the BsmI 
variant that therefore represents a risk factor for MM. The bb 
genotype was also significantly correlated with increased 
Breslow thickness, suggesting that vitamin D, through VDR 
(or another nearby linked gene), influences MM aggressive-
ness or host resistance to tumour development. Br J Dermatol 
2007; 156:277–282.
Infliximab-induced clinical and biological 
autoimmunity in patients with severe psoriasis
It is known that treatment 
with tumour necrosis fac-
tor-α-blocking agents may 
induce the development of 
biological autoimmunity, 
mostly antinuclear antibod-
ies (ANA), in patients with 
rheumatological diseases. 
Poulalhon et al. investigated clinical and biological autoimmu-
nity in 28 patients with severe recalcitrant psoriasis receiving 
infliximab. They report a high prevalence of newly appearing 
ANA during treatment. Autoantibodies were mostly antidou-
ble-stranded DNA IgM (68%), while IgG isotypes were rarely 
detected (16%). Three patients developed nonerosive polyar-
thritis without additional criteria for systemic lupus. These data 
emphasize the need to monitor clinical symptoms of autoim-
munity, especially lupus erythematosus, in patients receiving 
infliximab. Br J Dermatol 2007; 156: 329–336.
Phase I/II study of topical imiquimod and 
intralesional interleukin-2 in the treatment of 
accessible metastases in malignant melanoma
Two per cent of patients diag-
nosed with melanoma will go on 
to develop skin metastases and 
the majority of these patients will 
have recurrent lesions. They often 
require repeated treatments with 
different modalities in an attempt 
to control their disease. This study 
suggests that a combination of 
topical imiquimod and intral-
esional interleukin-2 is effective 
at controlling disease that may not be suitable for surgery or 
isolated limb perfusion. Results showed that 50.5% of lesions 
responded to treatment, with 40.7% of these being complete 
responses with disappearance of the lesion. Br J Dermatol 
2007; 156: 337–345.
